目的 觀察并探討注射用益氣復(fù)脈（凍干）（YQFM）聯(lián)合順鉑對乳腺癌荷瘤小鼠的抗腫瘤作用。方法 接種4T1腫瘤細(xì)胞懸液0.1 mL （細(xì)胞總數(shù)約1×10⁷）于SPF級BALB/C小鼠第4對乳頭下方的皮下脂肪墊制備乳腺癌模型。造模小鼠隨機分為模型組、順鉑（1 mg/kg）組、YQFM（914 mg/kg，臨床等效劑量）組、1/2順鉑（0.5 mg/kg）＋YQFM（914 mg/kg）組、順鉑（1 mg/kg）＋YQFM（914 mg/kg）組，各組小鼠均于接瘤后第7天開始給藥，順鉑均ip給藥，隔天給藥1次，共7次；YQFM均尾iv給藥，每天1次，共14 d。模型組同法給予9%氯化鈉注射液。觀察小鼠生活狀態(tài)、體質(zhì)量變化；檢測實體瘤質(zhì)量并計算抑瘤率；測量瘤體積變化；ELISA法檢測各組小鼠血清白細(xì)胞介素-2 （IL-2）、白細(xì)胞介素-4 （IL-4）、γ-干擾素（IFN-γ）、乳酸脫氫酶（LDH）和腫瘤壞死因子-α （TNF-α）、腺嘌呤核苷三磷酸（ATP）水平。結(jié)果 與模型組比較，順鉑組、順鉑＋YQFM、1/2順鉑＋YQFM組小鼠從順鉑第3次給藥左右開始出現(xiàn)毛發(fā)稀疏、掉毛嚴(yán)重、發(fā)呆、行動遲緩、喜抱團等現(xiàn)象，1/2順鉑＋YQFM組比單純順鉑組稍好。與模型組比較，YQFM組體質(zhì)量顯著增加（P<0.05、0.001）；順鉑組體質(zhì)量增長顯著減緩（P<0.05、0.001）； 1/2順鉑＋YQFM組和順鉑＋YQFM組2組小鼠體質(zhì)量無顯著性差異。與模型組比較，順鉑組、1/2順鉑＋YQFM組及順鉑＋YQFM組瘤質(zhì)量均顯著減輕（P<0.05），YQFM＋順鉑組的抑瘤率最佳，1/2順鉑+YQFM組與順鉑組抑瘤效果相當(dāng)。與模型組比較，順鉑＋YQFM組、順鉑組、1/2順鉑＋YQFM組分別是在給藥后第7、9、11天時瘤體積出現(xiàn)顯著降低（P<0.05）。與模型組比較，順鉑組、1/2順鉑＋YQFM組及YQFM＋順鉑均能夠顯著提高IL-2、IL-4、IFN-γ、TNF-α水平和降低ATP的含量（P<0.01、0.001）；順鉑組和1/2順鉑＋YQFM組的LDH含量顯著提高（P<0.05）； YQFM也能顯著性提高IL-2、IFN-γ、TNF-α含量和降低ATP的含量水平（P<0.01、0.001）。與順鉑組比較，1/2順鉑＋YQFM組的TNF-α含量顯著降低（P<0.01）。結(jié)論 YQFM與順鉑聯(lián)合使用對乳腺癌荷瘤小鼠具有一定的增效協(xié)同作用。

Objective To observe and investigate the anti-tumor effect of Yiqi Fumai Lyophilized Injection (YQFM) combined with cisplatin on breast cancer-bearing mice. Methods The breast cancer model was prepared by inoculated 0.1 mL of 4T1 tumor cell suspension (about 1×10⁷ cells) into the subcutaneous fat pad below the fourth pair of nipples of SPF BALB/C mice. Model mice were randomly divided into model group, cisplatin (1 mg/kg) group, YQFM (914 mg/kg, clinical equivalent dose) group, 1/2 cisplatin (0.5 mg/kg) +YQFM (914 mg/kg) group, cisplatin (1 mg/kg) +YQFM (914 mg/kg) group, Mice in each group were given cisplatin on the 7th day after tumor grafting, and cisplatin was given ip once every other day for 7 times in total. YQFM was given iv medication, once a day, for 14 days. Model group was given 9% sodium chloride injection. Life status and body weight of mice were observed. The quality of solid tumor was detected and the tumor inhibition rate was calculated. The change of tumor volume was measured. Serum interleukin-2 (IL-2), interleukin-4 (IL-4), γ -interferon (IFN-γ), lactate dehydrogenase (LDH) and tumor necrosis factor -α (TNF-α) and adenine nucleoside triphosphate (ATP) levels were detected by ELISA. Results Compared with model group, mice in cisplatin group, cisplatin + YQFM group and 1/2 cisplatin +YQFM group began to show hair thinning, severe hair loss, trance, slow movement, and agglutination from about the third administration of cisplatin, and the 1/2 cisplatin + YQFM group was slightly better than that in the single cisplatin group. Compared with model group, body weight of YQFM group was significantly increased (P<0.05, 0.001); The increase of body weight in cisplatin group was significantly decreased (P<0.05, 0.001); There was no significant difference in body weight between 1/2 cisplatin + YQFM group and cisplatin +YQFM group. Compared with the model group, the tumor weight of cisplatin group, 1/2 cisplatin + YQFM group and cisplatin +YQFM group was significantly reduced (P<0.05). The tumor inhibition rate of YQFM + cisplatin group was the best, and the tumor inhibition effect of 1/2 cisplatin +YQFM group was similar to that of cisplatin group. Compared with model group, tumor volume in cisplatin +YQFM group, cisplatin group and 1/2 cisplatin +YQFM group was significantly decreased on day 7, 9 and 11 after administration (P<0.05). Compared with model group, cisplatin group, 1/2 cisplatin +YQFM group and YQFM+ cisplatin group could significantly increase the levels of IL-2, IL-4, IFN-γ and TNF-α and decrease the content of ATP (P<0.01, 0.001). LDH content of cisplatin group and 1/2 cisplatin +YQFM group was significantly increased (P<0.05); YQFM also significantly increased the contents of IL-2, IFN-γ, TNF-α and decreased the content of ATP (P<0.01, 0.001). Compared with cisplatin group, the TNF-α content in 1/2 cisplatin +YQFM group was significantly decreased (P<0.01). Conclusion YQFM combined with cisplatin has a certain synergistic effect on breast cancer bearing mice.

R285.5